CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

  1. Segal, N.H.
  2. Melero, I.
  3. Moreno, V.
  4. Steeghs, N.
  5. Marabelle, A.
  6. Rohrberg, K.
  7. Rodriguez-Ruiz, M.E.
  8. Eder, J.P.
  9. Eng, C.
  10. Manji, G.A.
  11. Waterkamp, D.
  12. Leutgeb, B.
  13. Bouseida, S.
  14. Flinn, N.
  15. Das Thakur, M.
  16. Elze, M.C.
  17. Koeppen, H.
  18. Jamois, C.
  19. Martin-Facklam, M.
  20. Lieu, C.H.
  21. Calvo, E.
  22. Paz-Ares, L.
  23. Tabernero, J.
  24. Argilés, G.
Revue:
Nature Communications

ISSN: 2041-1723

Année de publication: 2024

Volumen: 15

Número: 1

Type: Article

DOI: 10.1038/S41467-024-48479-8 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus